Massive Bio is a provider of personalized oncology solutions, connecting patients to leading-edge therapies and clinical trials worldwide. The company leverages Telehealth, Genomics, AI, Concierge Services, and Smart Data for patient and provider engagement in cancer clinical trials.

Selin Kurnaz

Cagatay Culcuoglu

Arturo Loaiza-Bonilla

Massive Bio

Health in Code specializes in genetic testing and provides solutions for the prevention, diagnosis, prognosis, and treatment of hereditary diseases. The company offers a variety of genetic tests and bioinformatics software.

Health in Code

Massive Bio Blog

Increasing Accessibility to Clinical Trials and Personalized Cancer Treatment Options.

Every cancer patient is different and deserves treatment of the highest quality that is personalized, affordable, and easily accessible.

Massive Bio translates the world-class oncology knowledge of the large cancer centers' experts, facilitates a virtual tumor board collaboratively with the treating oncologist, and advises the patient and treating oncologist to operationalize these expert recommendations at the point of care thereby, eliminating additional time, travel, and cost. 

85% of US cancer patients receive treatments in community practices where treating oncologists are overwhelmed with the influx of new tests and treatments while trying to manage their busy practices. We believe all cancer patients deserve equal access to the latest in cancer research and treatment.

UL Ventures

International Private Bank (IPB)

Revo Capital

Cavendish Impact Capital

Princeton Alumni Angels

Gyan Kapur

500 Global

Charles and Lynn Schusterman Family Philanthropies

Schusterman Foundation

KFW DEG

Deutsche Investitions- und Entwicklungsgesellschaft mbH

IFC Asset Management Company

ImpactAssets

SiteGround

THE CATALYTIC IMPACT FOUNDATION (CIF)

Toyota Financial Services

Kenan Turnacioglu

Selin Kurnaz, PhD, Co-founder and CEO of Massive Bio, is set to attend the prestigious SCOPE Summit for Clinical Ops Executives from February 11-14, 2024, in Orlando, Florida.

🚀 Why It's Exciting:
- The SCOPE Summit is a key event for innovations in clinical trials.
- Selin will bring her expert insights to the summit, highlighting Massive Bio's commitment to advancing medical knowledge and improving patient care.

🔜 Stay tuned for a special announcement from Massive Bio before the summit.
👉 More about the summit at SCOPE Summit 2024.

Join us in shaping the future of clinical trials!
#SCOPE2024 #MassiveBio #ClinicalTrials #DigitalHealth #Innovation

https://lnkd.in/dvy4VpfA

🌟 Introducing Marta Halke-Markiewicz Our Account Manager & Business Development for Poland and Germany! 🌟

Marta is at the forefront of our mission to revolutionize healthcare in Poland and Germany. As our dedicated Account Manager, she is responsible for building robust patient identification channels and fostering strategic partnerships. Her unwavering commitment and extensive experience are instrumental in expanding Massive Bio's presence in these regions, driving growth, and strengthening relationships with healthcare providers.

Beyond her professional life, Marta is passionate about exploring new cultures through travel, mastering languages, and cooking.

Thank you for being an invaluable part of our team!

Selin Kurnaz, PhD, Arturo LoAIza-Bonilla MD, Çağatay M. Çulcuoğlu

🚀 #MassiveBio #Healthcare #Innovation

Welcome, David Hurtado de Mendoza to the Massive Bio Family! 🎉
 
Dr. David Hurtado de Mendoza, a board-certified Internal Medicine attending, is a graduate of Cayetano Heredia University in Peru. 
 
With a robust academic foundation and extensive experience from renowned institutions such as the University of Oxford, Johns Hopkins University, and the University of Miami, where he completed his postgraduate training, he brings enthusiasm to his new role as Senior VP for Operations & Strategy. 

Dr. Hurtado de Mendoza is dedicated to global bridging patients and healthcare providers with state-of-the-art technology and clinical trials. 
 
His passion for healthcare improvement is evident in his commitment to exercise and his appreciation for cultural diversity through music. 
 We eagerly anticipate his contributions to our team. 
 
Let's celebrate David joining our company.
 
Selin Kurnaz, PhD, Arturo LoAIza-Bonilla MD, Çağatay M. Çulcuoğlu, Aycan Emre
 
#MassiveBio #Operations&Strategy #HealthcareImprovement

We're thrilled to announce that the American Cancer Society has spotlighted our Co-Founder and Chief Medical Officer, Arturo LoAIza-Bonilla MD, for his outstanding contributions to oncology. Dr. Arturo's innovative leadership has been pivotal in reshaping cancer care through personalized treatment strategies at Massive Bio.

Under his guidance, we've seamlessly integrated AI with medical expertise, creating platforms that connect cancer patients with tailored clinical trials and novel therapies. This approach not only mirrors Dr. Arturo's patient-first philosophy but also resonates with the American Cancer Society's mission to enhance patient care and support.

This accolade underscores our dedication to healthcare innovation, equitable access, and our relentless drive towards a future where every cancer patient has access to personalized care. Kudos to Dr. Arturo for his visionary leadership and to our team for pushing the boundaries of cancer treatment!

Selin Kurnaz, PhD, Arturo LoAIza-Bonilla MD, Çağatay M. Çulcuoğlu

🔬✨ #CancerCare #Innovation #HealthcareLeadership #PersonalizedMedicine #MassiveBio

Our CEO, Selin Kurnaz, PhD, has been recognized in the prestigious list of "12 Women-Led Biotech Companies That Crushed It in 2023" by Biotech Metropolitan Women 🏆. This honor underscores her role in propelling Massive Bio to new heights in global cancer care. Under her leadership, we've forged key partnerships with seven organizations, broadening access to clinical trials and advanced cancer treatments.

Highlighting our commitment to innovation, Massive Bio introduced state-of-the-art Chat GPT-4 AI chatbots at ASCO 2023 🤖, revolutionizing patient engagement and advancing personalized cancer care.

With Dr. Kurnaz at the helm, Massive Bio is steadfast in its mission to democratize cancer care, making pioneering treatments accessible to everyone. 🌍

Selin Kurnaz, PhD, Arturo LoAIza-Bonilla MD, Çağatay M. Çulcuoğlu

#HealthcareInnovation #Biotech #CancerCare #Leadership #AIRevolution

Our CEO Selin Kurnaz, PhD and CFO Toygun Onaran are gearing up for the prestigious J.P. Morgan 2024 Healthcare Conference in San Francisco next week! 
 
We're thrilled to be a part of this influential event, connecting with industry leaders, innovators, and visionaries.
 
🤝 If you're attending, we'd love to connect! 
 
📆 The countdown has begun for the event in which Massive Bio leaders will participate between January 7-10. Save the date and stay tuned for updates from the conference as we continue our mission to revolutionize healthcare and make a lasting impact. 🌐💡

Selin Kurnaz, PhD, Arturo LoAIza-Bonilla MD, Çağatay M. Çulcuoğlu 

#JPMorganHealthcareConference #HealthcareInnovation #Leadership #Networking #HealthcareRevolution

Our Co-founder, Çağatay M. Çulcuoğlu, recently joined an insightful AI Event at Haliç University. 🎓 He passionately delved into the world of Artificial Intelligence and shed light on how Massive Bio is actively shaping the future through groundbreaking developments. 💡
 
Cagatay shared invaluable insights, highlighting the incredible strides Massive Bio is making in the AI landscape. 

Selin Kurnaz, PhD, Arturo LoAIza-Bonilla MD, Çağatay M. Çulcuoğlu
 
#MassiveBio #AIInnovation #FutureForward #HalicUniversityEvent #AIRevolution

🚀 Exciting Milestones and Future Goals at Massive Bio
 
As we embrace the new year, we are thrilled to share our company's significant achievements and set our ambitious objectives for 2024. Wishing everyone a Happy and Healthy New Year!
 
📌 Recent Achievements:
▶ Increased Clinical Trials: We've achieved a significant milestone with 78 clinical trials, a substantial increase from 50 last year.
▶ Expanded Customer Base: Our partnerships now include 29 esteemed pharmaceutical companies, reflecting the growing trust in our solutions.
▶ Pharma Commercial Product Success: We've enhanced how companies locate patients, making the process more effective.
▶ Collaborations with Industry Leaders: Proudly serving 6 of the top 10 CROs, our impact in the industry continues to grow.
▶ Extensive Network: We're collaborating with 275 patient advocacy groups, 2,850 referring physicians, 30 hospitals, and 30 strategic partners, broadening our outreach and impact.
 
📌 Future Goals:
▶ Patient Enrollment: We aim to enroll 250,000 cancer patients in our program, offering them hope and advanced care options.
▶ Trial Expansion: We aim to increase our trial count to 200, furthering our research and treatment capabilities.
▶ Customer Upgrade: We're focused on upgrading 75% of our customers to multi-trial programs, enhancing the quality of our partnerships.
▶ Global Expansion: We are expanding our business into 14 countries across Europe, LATAM, and Asia, including Argentina, Colombia, the Czech Republic, Denmark, Finland, Iceland, Japan, Mexico, Norway, Peru, South Korea, Sweden, Taiwan, and the United Kingdom.
▶ Innovative Product Launch: We're gearing up to launch a groundbreaking new product that transforms patient pre-screening.
▶ Internal Investment: A significant focus will be investing in our company, especially growing patient enrollment.
 
📌 Our Vision for 2024:
In 2024, we aim to reach more cancer patients and create positive changes in their lives and the lives of their loved ones. We are dedicated to making a meaningful difference in cancer care and patient support.
 
The journey has been inspiring, and the path is full of promise. Thanks to our team, partners, and clients who are integral to our success. Let’s continue to make strides in healthcare innovation together!
 
Selin Kurnaz, PhD, Arturo LoAIza-Bonilla MD, Çağatay M. Çulcuoğlu

#CancerCare #ClinicalTrials #GlobalHealth #Innovation #PatientSupport #HealthcareGoals2024 #MassiveBio

Big News from Fast Company Event! 

Toygun Onaran, our CFO at Massive Bio, showcased our impact in advanced cancer treatment with our AI-driven platform and 2023's strategic milestones.

🌱 Plus, we're excited to announce Massive Bio ranked second in Fast Company's Startup 100 in Turkey!

Thanks to everyone who made this success possible.

🚀 Here's to continued innovation and growth in 2024!
Selin Kurnaz, PhD, Arturo LoAIza-Bonilla MD, Çağatay M. Çulcuoğlu

#MassiveBio #HealthTech #FastCompany #Startup100 #Innovation

Our dedication to innovation and health technology has been recognized with the prestigious "Aim for Global Success" award at the "Entrepreneurs of Türkiye Awards Ceremony." This achievement celebrated during Türkiye Innovation Week on November 25, 2023, reflects our commitment to shaping the global healthcare landscape. We extend our deepest gratitude to everyone who contributed to this success, fueling our determination to continue making impactful strides in the global tech sector. 🏆🚀

Arturo LoAIza-Bonilla MD, Selin Kurnaz, PhD, Çağatay M. Çulcuoğlu, Aycan Emre
 #GlobalSuccess #InnovationMilestone

Metric
Company Name	Massive Bio	Health in Code
Symbol
MSH ID	COM:MASSIVEBIO	COM:HEALTHINCODE
Market	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare & Health Services
Industry	Healthcare & Health Services	Genetics
Country	US	ES
Stage	Series B
Employee Count	83
Website	massivebio.com	healthincode.com
LinkedIn	massivebio
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	62.05K
Web Traffic Growth	-0.53
Valuation
Raised Capital	17M

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:MASSIVEBIO

Massive Bio

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue